Clinical Isolate Core (Core B)

项目总结/摘要 临床分离株核心（核心B）的总体目标是提供对临床分离株的稳健收集的访问。 细菌分离株和用于评价抗生素的标准化和实验控制平台 Heteroresistance Interdisciplinary Research Unit（HR-IRU）的Heteroresistance（HR）。因此，核心B是 这对HR-IRU计划的整体成功至关重要。为了实现核心目标，我们已经组建了一个 多学科团队，包括传染病临床医生（雅各布），研究科学家（萨托拉），董事会， 认证医学微生物学家（Burd）和一名流行病学家（Tunali），在抗生素领域拥有广泛的专业知识 阻力对于核心B，使我们能够成功完成研究项目，并促进我们的理解 针对抗生素HR，我们提出了三个具体目标。1)提供临床细菌分离株。分离株 （肠球菌和鲍曼不动杆菌复合菌）将作为疾病中心的一部分收集 控制和预防（CDC）格鲁吉亚新发感染项目（EIP）多地点革兰氏阴性 埃默里大学临床微生物学研究核心（ICMC）监测倡议（MuGSI） 生物储存库和瑞典乌普萨拉大学医院。2)为HR分析临床细菌分离株。我们将 每年从血液、尿液和呼吸道临床感染中检测500个细菌分离株：200个多药 来自格鲁吉亚EIP的100个耐药微生物（MDRO）;来自ICMC的100个非MDRO和200个主要耐药微生物（MDRO） 来自瑞典乌普萨拉大学医院的敏感分离株。将对每株分离株进行HR检测， 使用群体分析谱（PAP），HR的金标准，大约20种抗生素。 进行流行病学分析，以揭示人力资源的患病率、类型和趋势。 目标2中检测的2500株分离株的HR。我们将进行全面的描述性流行病学对 HR分离株的临床和实验室特征，并与无HR分离株进行比较。核心B将 在格鲁吉亚EIP和埃默里大学ICMC的实验室进行，这些实验室有广泛的 核心领导层将与以下人员密切合作： HR-IRU项目主管/PI和项目负责人，以确保严格满足所有项目的需求 以可靠、可复制和及时的方式。

PROJECT SUMMARY/ABSTRACT The overall objective of the Clinical Isolate Core (Core B) is to provide access to a robust collection of clinical bacterial isolates and a standardized and experimentally controlled platform for evaluating antibiotic heteroresistance (HR) for the Heteroresistance Interdisciplinary Research Unit (HR-IRU). Core B is therefore essential to the overall success of the HR-IRU program. To accomplish Core goals, we have assembled a multidisciplinary team including an infectious disease clinician (Jacob), a research scientist (Satola), a board- certified medical microbiologist (Burd) and an epidemiologist (Tunali) with expertise vast areas of antibiotic resistance. For Core B to enable successful completion of the research projects and advance our understanding of antibiotic HR we propose three specific aims. 1) To provide access to clinical bacterial isolate. Isolates (Enterobacterales and Acinetobacter baumanii complex) will be collected as part of the Centers for Disease Control and Prevention's (CDC) Georgia Emerging Infections Program (EIP) Multi-site Gram-negative Surveillance Initiative (MuGSI), Emory University's Investigational Clinical Microbiology Core (ICMC) biorepository, and Uppsala University Hospital, Sweden. 2) To profile clinical bacterial isolates for HR. We will test 500 bacterial isolates per year from bloodstream, urine, and respiratory clinical infections: 200 multi-drug resistant organisms (MDRO) from the Georgia EIP; 100 non-MDRO from the ICMC and 200 predominately susceptible isolates from Uppsala University Hospital, Sweden. Each isolate will be tested for HR to approximately 20 antibiotics using population analysis profiling (PAP), the gold standard for HR. 3) To perform epidemiological analyses revealing the prevalence, type and trends of HR. We will establish the prevalence of HR from the 2500 isolates tested in aim 2. We will perform comprehensive descriptive epidemiology on the clinical and laboratory characteristics of isolates with HR and compare those to isolates without HR. Core B will be conducted in the laboratories of the Georgia EIP and Emory University's ICMC, which have extensive expertise in active-population based surveillance and studies of HR. The Core leadership will work closely with the HR-IRU program directors/PIs and project leaders to ensure that the needs of all projects are rigorously met in a reliable, reproducible and timely manner.